Immune-Mediated Inflammatory Responses of Alveolar Epithelial Cells: Implications for COVID-19 Lung Pathology
Overview
Authors
Affiliations
Background: Clinical and experimental evidence point to a dysregulated immune response caused by SARS-CoV-2 as the primary mechanism of lung disease in COVID-19. However, the pathogenic mechanisms underlying COVID-19-associated ARDS (Acute Respiratory Distress Syndrome) remain incompletely understood. This study aims to explore the inflammatory responses of alveolar epithelial cells to either the spike S1 protein or to a mixture of cytokines secreted by S1-activated macrophages.
Methods And Results: The exposure of alveolar A549 cells to supernatants from spike-activated macrophages caused a further release of inflammatory mediators, with IL-8 reaching massive concentrations. The investigation of the molecular pathways indicated that NF-kB is involved in the transcription of IP-10 and RANTES, while STATs drive the expression of all the cytokines/chemokines tested, with the exception of IL-8 which is regulated by AP-1. Cytokines/chemokines produced by spike-activated macrophages are also likely responsible for the observed dysfunction of barrier integrity in Human Alveolar Epithelial Lentivirus-immortalized cells (hAELVi), as demonstrated by an increased permeability of the monolayers to mannitol, a marked decrease of TEER and a disorganization of claudin-7 distribution.
Conclusion: Upon exposure to supernatants from S1-activated macrophages, A549 cells act both as targets and sources of cytokines/chemokines, suggesting that alveolar epithelium along with activated macrophages may orchestrate lung inflammation and contribute to alveolar injury, a hallmark of ARDS.
Areny-Balaguero A, Camprubi-Rimblas M, Campana-Duel E, Sole-Porta A, Ceccato A, Roig A Pharmaceutics. 2024; 16(10).
PMID: 39458645 PMC: 11510928. DOI: 10.3390/pharmaceutics16101316.
Chittasupho C, Umsumarng S, Srisawad K, Arjsri P, Phongpradist R, Samee W Pharmaceutics. 2024; 16(6).
PMID: 38931873 PMC: 11206841. DOI: 10.3390/pharmaceutics16060751.
Recchia Luciani G, Barilli A, Visigalli R, Sala R, DallAsta V, Rotoli B Int J Mol Sci. 2024; 25(6).
PMID: 38542436 PMC: 10970306. DOI: 10.3390/ijms25063463.
Sideratou C, Papaneophytou C Infect Dis Rep. 2023; 15(6):806-830.
PMID: 38131885 PMC: 10742861. DOI: 10.3390/idr15060072.
Barilli A, Recchia Luciani G, Visigalli R, Sala R, Soli M, DallAsta V Biomedicines. 2023; 11(10).
PMID: 37893073 PMC: 10603955. DOI: 10.3390/biomedicines11102699.